Fractures, Closed Clinical Trial
Official title:
The Use of Neuromuscular Electrical Muscle Stimulation With Pelvic Fracture Rehabilitation: A Double Blind, Placebo Controlled, Randomised Control Trial
The purpose of the study is to investigate if using an electrical stimulation machine to see
if it can help strengthen the muscles around the hip during the first three months post
pelvic fracture will help with the early stages of rehabilitation. Electrical stimulation is
a treatment machine that uses an electrical current to cause a single muscle or a group of
muscles to contract. This contraction helps strengthen injured muscles and helps with the
healing process. It can also help with pain relief by blocking pain signals from the brain.
After a pelvic fracture they are surgically fixed and will be advised not to put any weight
on the operated leg for 10 weeks. During this time hip muscles become very weak as they will
not be used as much as normal. Bed exercises can help keep muscle strength but this study
would like to try using electrical stimulation machines alongside bed exercises to see if it
can improve muscle strength even more. Electrical stimulation machines are already used by
rehabilitation. Electrical stimulation is a treatment machine that uses an electrical current
to cause a single muscle or a group of muscles to contract. This contraction helps strengthen
injured muscles and helps with the healing process. It can also help with pain relief by
blocking pain signals from the brain.
After a pelvic fracture they are surgically fixed and will be advised not to put any weight
on the operated leg for 10 weeks. During this time hip muscles become very weak as they will
not be used as much as normal. Bed exercises can help keep muscle strength but this study
would like to try using electrical stimulation machines alongside bed exercises to see if it
can improve muscle strength even more. Electrical stimulation machines are already used by
patients to increase muscle strength.
Participants will be put into one of two groups, both groups will be given an electrical
stimulation machine but one will be on a placebo setting. Participants will need to use the
machine twice a day along with their bed exercises and will need to fill in a diary when and
how many times the machine has been used for 10 weeks until their 12 week appointment with
the orthopaedic consultant. The participants weight bearing status will change and they will
be asked to perform a muscle strength test on both the operated and nonoperated leg. They
will also have their walking quality assessed. The results will compare both groups for
muscle strength and walking changes.
All subjects who wish to enter the study will be fully screened and consented by the Chief
Investigator, or an appropriate delegate. The Royal London is the largest major trauma centre
in London and fixes more pelvic fractures than any other hospital. The orthopedic team will
surgically fix between two and six pelvic fractures per week which should meet the inclusion
criteria. Pelvic fractures are surgically fixed and then will be instructed to put no weight
through the operated limb for 10-12 weeks by the orthopedic consultant. The physiotherapist
will give the patient a bed exercise programme day one post operation as per standard
practice which consists of hip range of movement exercises and gentle strengthening exercises
for muscles around the hip and thigh.
The chief investigator will be part of the patient's normal healthcare team and will identify
eligible participants. The participants will be recruited one week post operation to give the
patient time to recover from their surgery but not allow for loss in muscle mass. The
research assistant will approach the participant 24 hours prior to this and explain the
demands of the study and what it will involve allowing the participant 24 hours to discuss
this with family members.
After the 24 hour period the chief investigator will also be present to answer any questions
about the study. The participant will be expected to provide written informed consent and
will be expected to sign the treatment contract which outlines the responsibilities of the
participant and the chief investigator. On discharge a six week follow up appointment in
fracture clinic will be arranged in which both the consultant and chief investigator will be
present to complete the EQ5D questionnaire and monitor compliance within the first six weeks
of the intervention. At 10 weeks the participant will have a further fracture clinic
appointment in which they are expected to bring back the machine and make a short journey to
the human performance laboratory and Queen Mary's University to complete their gait analysis
and strength testing along with a further EQ5D questionnaire, this will be the end of the
study and the participants are free to leave.
Randomisation procedure
Simple random sampling will be used with a free randomisation computer programme
(www.sealedenvelopes.co.uk). When the patient has consented to the study the chief
investigator will enter the participant unique study number into the website whilst the
participant can read the patient information sheet and treatment contract and it will
randomly allocate into treatment (NMES) or placebo (TENS) group. If a participant withdrew
from the study a new participant could not replace this participant but be randomly allocated
into a group as a new patient.
Blinding/ Emergency unblinding
The independent assessor will be blinded to participant allocation when testing at 10 weeks
for both the gait analysis and peak torque measurements. All participants will be blinded to
group allocation and will all be given identical machines on different settings. The
principle investigator will complete the randomisation procedure and will be aware of group
allocation for monitoring and safety purposes.
Treatment/intervention plan and rationale
Patients allocated to the NMES group will be given an information booklet on NMES machines
and the principle researcher will explain and demonstrate how to use the machines. The Cefar
Compex three electrical stimulator will be used and demonstrates valid results from previous
studies (Billot et al 2010., Gondin et al 2005., and Maffiuletti et al., 2002).
Participants are expected to use the NMES machine for half an hour and complete bed exercises
twice daily. They will be activating two of their muscles at the same time and will not be
expected to complete the bed exercises and NMES together. Patients should relax during the
NMES as completing both does not demonstrate better results, due to unsynchronised activation
of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the
recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high
intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
Participants will use the muscle reinforcement rehabilitation protocol below which increases
from 4Hz to 85Hz allowing slow and fast twitch muscle fibre recruitment. This protocol is
used for participants who have had minimal loss of muscle bulk and starts with small currents
and slowly builds up as the patient becomes accustom to the sensation of the machine.
Patients are expected to increase the intensity, as higher intensity can increase activation
of more muscle fibres (Stevens-Lapsley et al, 2012).
Additional treatment/ interventions
The placebo group will act as the control group. They will be expected to complete the same
regime as previously described above, however these machines will be on TENS setting
(80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is
designed as a sensory stimulus therefore will have no effects on muscle strength however the
patient will feel a small twitch sensation. This setting is not painful and will have no
effect on muscle fatigue. The patient will not be expected to complete the bed exercises and
the TENS session together.
Experts within orthopedic rehabilitation concluded a 20% difference between operated and
non-operated post intervention would be of clinical relevance. A randomized feasibility study
was completed previously in which the results were used to calculate a power calculation for
this specific trial. The value of 0.25 represents the standard deviation achieved when
comparing the NMES and the placebo group in the previous study. The 0.2 is 20% calculated
into a ratio which is needed to achieve clinical relevance. This power calculation indicates
25 participants are needed for each group to achieve statistical significance 50 participants
in total. The orthopedic team will surgically fix between two and six pelvic fractures per
week which should meet the inclusion criteria. Dropout rates will be small as it is a six
week intervention. Patients will receive weekly phone calls and text reminders monitoring
compliance.
N= (1.96+0.84)2 x 2 x 0.252 0.22 = 25 per group (50 in total)
0.2/ 0.25 = the standard deviation achieved when comparing treatment to placebo in peak
torque differences
0.2 = is the ratio / 20% difference between the treatment and placebo group in abductors
An independent experimental design using an independent test will be suitable to assess the
data for this study. Both the placebo and NMES group will have different interventions and
will therefore not be measured using a pre and post design. Due to the adequate sample size
it will be appropriate to use a parametric statistical test. A Paired T-test will be used to
analyse the data from the EQ5D questionnaire as they are taken at six and 12 weeks during the
intervention with the same participants.
A Spearman's rank correlation test will be used to compare changes with compliance levels in
both bed exercises and NMES use in the NMES group and compared to the changes in peak torque
to assess the relationship between the two variables. The same will be completed between the
intensity level of the NMES and the changes in peak torque within the NMES group. Variables
can be seen in table format below:
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03781817 -
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
|
Phase 4 | |
Recruiting |
NCT03796572 -
Regional Blocks for Lateral Condyle Fractures
|
Phase 4 | |
Recruiting |
NCT02957240 -
Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures
|
N/A | |
Terminated |
NCT03196258 -
Cognitive Behavioural Therapy to Reduce Persistent Post-Surgical Pain After Fracture
|
N/A | |
Terminated |
NCT05655130 -
Distal Radius Steroid
|
Phase 1 | |
Not yet recruiting |
NCT06400732 -
Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System
|
||
Terminated |
NCT00610701 -
Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures
|
N/A | |
Completed |
NCT03991546 -
Pain and Narcotic Usage After Orthopaedic Surgery
|
N/A | |
Completed |
NCT00843973 -
Osteogenic Cell Viability in Bone Graft
|
N/A | |
Recruiting |
NCT04730739 -
FastFrame Knee Spanning and Damage Control Kit PMCF
|
N/A | |
Completed |
NCT03525821 -
Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)
|
Phase 3 | |
Completed |
NCT04026074 -
Concepts for Analgosedation During Placement of Regional Anaesthesia Before Operations.
|
Phase 4 | |
Withdrawn |
NCT01812863 -
Pain Management in Children Undergoing Supracondylar Humerus Fracture Repair
|
N/A | |
Terminated |
NCT03673358 -
Cognitive Behavioural Therapy to Optimize Post-Operative Recovery Pilot
|
N/A | |
Recruiting |
NCT04274530 -
Cognitive Behavioural Therapy to Optimize Post-Operative Recovery Trial
|
N/A | |
Completed |
NCT00610987 -
Antibiotic Prophylaxis in Orthopaedic Traumatology
|
N/A | |
Recruiting |
NCT06130397 -
AI Assisted Detection of Fractures on X-Rays (FRACT-AI)
|
||
Completed |
NCT02390856 -
Volar Plate vs. Conventus DRS Fixation
|
N/A | |
Recruiting |
NCT05260463 -
LOQTEQ® Antibacterial Pre-Market Study
|
N/A | |
Completed |
NCT00829621 -
Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)
|
N/A |